Intro

This chapter examines the recent decline in market performance, highlighting the struggles of Novo Nordisk shares linked to underwhelming trial results for its obesity drug, Cagri Sema. Additionally, it addresses the contrasting fortunes of competitors and provides insights into the broader crypto market and inflation trends.